Takeda's Deal to Buy Valeant's Salix Falls Apart

Nov. 30, 2016

After early reports that Takeda Pharmaceutical's negotiations to buy Valeant's Salix stomach-drug biz were breaking down over price, Bloomberg has reported that Valeant will keep its Salix business.

Earlier this month, news sources reported that Valeant was in advanced talks to sell its Salix business to Japan’s Takeda for about $10 billion.

The sale fallout will put increased pressure on Valeant to find a way to settle its $30 billion debt.

Valeant announced in a press release on Tuesday that it was making a “significant” expansion in the size of the sales force for two Salix products, gastrointestinal treatment Xifaxan and constipation treatment Relistor.